[Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on dyslipidemia and thyroid disorders]

Pathol Biol (Paris). 2013 Aug;61(4):168-70. doi: 10.1016/j.patbio.2013.07.010. Epub 2013 Sep 4.
[Article in French]

Abstract

In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the third annual series of workshops which brought together practitioners from all member centers and took place in October 2012 in Lille. Here we report our results and recommendations regarding the management of short and long-term endocrine dysfunction following allogeneic stem cell transplantation. The key aim of this workshop was to give an overview on dyslipidemia and thyroid disorders post-transplant.

Keywords: Allogeneic stem cell transplantation; Allogreffe de cellules souches hématopoïétiques; Dyslipidemia; Dyslipidémie; Guideline; Metabolic dysfunction; Thyroid disorders; Thyropathie; Troubles métaboliques.

Publication types

  • English Abstract
  • Practice Guideline

MeSH terms

  • Choice Behavior
  • Consensus
  • Diet
  • Dyslipidemias / etiology
  • Dyslipidemias / therapy*
  • Endocrine System Diseases / etiology*
  • Endocrine System Diseases / therapy*
  • Fibric Acids / therapeutic use
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hematopoietic Stem Cell Transplantation / standards
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Monitoring, Physiologic / methods
  • Monitoring, Physiologic / standards
  • Thyroid Diseases / etiology
  • Thyroid Diseases / therapy*
  • Transplantation, Homologous

Substances

  • Fibric Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors